Bristol-Myers Squibb Company (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its type II variation application, which ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo (nivolumab) for Treatment of Patients with Resected High-Risk Advanced MelanomaOctober 30, 2017 6:59 AM SunTrust Robinson Humphrey Upgrades Bristol-Myers Squibb Co. (BMY) to BuyOctober 30, 2017 6:47 AM Bristol-Myers Squibb (BMY) Weakness Unwarranted - JPMorganOctober 26, 2017 1:04 PM Bristol-Myers Squibb (BMY) Misses Q3 EPS by 2c, Beats on Revenues; Lowers FY17 EPS Guidance October 26, 2017 7:01 AM